ES2431963T3 - Partícula viral adyuvante - Google Patents
Partícula viral adyuvante Download PDFInfo
- Publication number
- ES2431963T3 ES2431963T3 ES03739913T ES03739913T ES2431963T3 ES 2431963 T3 ES2431963 T3 ES 2431963T3 ES 03739913 T ES03739913 T ES 03739913T ES 03739913 T ES03739913 T ES 03739913T ES 2431963 T3 ES2431963 T3 ES 2431963T3
- Authority
- ES
- Spain
- Prior art keywords
- papmv
- virus
- particle
- protein
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002245 particle Substances 0.000 title claims abstract description 98
- 239000002671 adjuvant Substances 0.000 title claims abstract description 40
- 230000003612 virological effect Effects 0.000 title description 16
- 241000709995 Papaya mosaic virus Species 0.000 claims abstract description 154
- 108091007433 antigens Proteins 0.000 claims abstract description 68
- 102000036639 antigens Human genes 0.000 claims abstract description 68
- 239000000427 antigen Substances 0.000 claims abstract description 67
- 241000700605 Viruses Species 0.000 claims abstract description 53
- 230000028993 immune response Effects 0.000 claims abstract description 50
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 44
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 241001465754 Metazoa Species 0.000 claims abstract description 25
- 229960005486 vaccine Drugs 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 102100021696 Syncytin-1 Human genes 0.000 claims abstract description 21
- 101710091045 Envelope protein Proteins 0.000 claims abstract description 20
- 101710188315 Protein X Proteins 0.000 claims abstract description 20
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 15
- 108700030444 papaya mosiac virus coat Proteins 0.000 claims abstract 4
- 230000002708 enhancing effect Effects 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 25
- 230000004044 response Effects 0.000 claims description 22
- 108020001507 fusion proteins Proteins 0.000 claims description 20
- 102000037865 fusion proteins Human genes 0.000 claims description 20
- 241000711549 Hepacivirus C Species 0.000 claims description 17
- 230000004927 fusion Effects 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 238000002255 vaccination Methods 0.000 claims description 10
- 230000000890 antigenic effect Effects 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 241000607142 Salmonella Species 0.000 claims description 6
- 230000005923 long-lasting effect Effects 0.000 claims description 6
- 230000015654 memory Effects 0.000 claims description 5
- 230000024932 T cell mediated immunity Effects 0.000 claims description 4
- 230000028996 humoral immune response Effects 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 3
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 238000011260 co-administration Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 description 46
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 23
- 108010078791 Carrier Proteins Proteins 0.000 description 16
- 239000013256 coordination polymer Substances 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 210000000987 immune system Anatomy 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 230000003053 immunization Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 230000002434 immunopotentiative effect Effects 0.000 description 8
- 241001112090 Pseudovirus Species 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 210000002845 virion Anatomy 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 108010013381 Porins Proteins 0.000 description 5
- 102000017033 Porins Human genes 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000000091 immunopotentiator Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000723655 Cowpea mosaic virus Species 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 241000710007 Potexvirus Species 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 241000287433 Turdus Species 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000006041 cell recruitment Effects 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940126578 oral vaccine Drugs 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000724328 Alfalfa mosaic virus Species 0.000 description 1
- 101100042610 Arabidopsis thaliana SIGB gene Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000219173 Carica Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108700008783 Hepatitis C virus E1 Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- SHFKGANKURXVMY-LCWPZEQJSA-N hcv e2 protein Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)CC1=CC=CC=C1 SHFKGANKURXVMY-LCWPZEQJSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 101150117326 sigA gene Proteins 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000000724 thymus hormone Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/26011—Flexiviridae
- C12N2770/26023—Virus like particles [VLP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39365902P | 2002-07-05 | 2002-07-05 | |
| US393659P | 2002-07-05 | ||
| PCT/CA2003/000985 WO2004004761A2 (en) | 2002-07-05 | 2003-06-30 | Adjuvant viral particle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2431963T3 true ES2431963T3 (es) | 2013-11-28 |
Family
ID=30115621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03739913T Expired - Lifetime ES2431963T3 (es) | 2002-07-05 | 2003-06-30 | Partícula viral adyuvante |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7641896B2 (enExample) |
| EP (2) | EP2272525A3 (enExample) |
| JP (1) | JP4953570B2 (enExample) |
| KR (1) | KR20050044886A (enExample) |
| CN (1) | CN1665528B (enExample) |
| AU (1) | AU2003281246A1 (enExample) |
| BR (1) | BR0312474A (enExample) |
| CA (1) | CA2434000C (enExample) |
| DK (1) | DK1523329T3 (enExample) |
| ES (1) | ES2431963T3 (enExample) |
| MX (1) | MXPA05000287A (enExample) |
| NO (1) | NO20050396L (enExample) |
| PT (1) | PT1523329E (enExample) |
| WO (1) | WO2004004761A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2434000C (en) * | 2002-07-05 | 2012-07-17 | Denis Leclerc | Adjuvant viral particle |
| US8101189B2 (en) | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
| JP2008513035A (ja) * | 2004-09-21 | 2008-05-01 | サイトス バイオテクノロジー アーゲー | Ａｐ２０５のコートタンパク質と抗原性ポリペプチドとの融合タンパク質を含んでなるウイルス粒子 |
| CN101119749A (zh) | 2004-10-25 | 2008-02-06 | 赛托斯生物技术公司 | 肠抑胃肽(gip)抗原阵列及其用途 |
| KR100688522B1 (ko) * | 2005-01-18 | 2007-03-02 | 삼성전자주식회사 | 영상데이터 압축기 및 압축방법 |
| WO2007053188A2 (en) | 2005-06-01 | 2007-05-10 | Dow Global Technologies, Inc. | Production of multivalent virus like particles |
| AT503690A1 (de) | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| EP2078086A4 (en) * | 2006-11-15 | 2010-06-30 | Folia Biotech Inc | PAPAYAMOSAIC VIRUS-BASED IMMUNOGENE AFFINITY-CONJUGATED ANTIGENSYSTEMS AND THEIR USES |
| WO2012048430A1 (en) * | 2010-10-14 | 2012-04-19 | Folia Biotech Inc. | Affinity-conjugated nucleoprotein-papaya mosaic virus-like particles and uses thereof |
| CA2669485C (en) * | 2006-11-15 | 2017-01-03 | Folia Biotech Inc. | Papaya mosaic virus-based vaccines for influenza |
| JP2010516713A (ja) * | 2007-01-26 | 2010-05-20 | フォーリア バイオテック インコーポレーテッド | 腸チフス菌および他の腸内細菌病原体に対するパパイアモザイクウィルスベースのワクチン |
| US20090093019A1 (en) * | 2007-04-27 | 2009-04-09 | Phelps Jamie P | Production and in vivo assembly of soluble recombinant icosahedral virus-like particles |
| JP2010538619A (ja) * | 2007-09-11 | 2010-12-16 | ユニベルシテ ラヴァル | Ｍａｌｖａモザイクウイルスおよびウイルス様粒子およびこれらの使用 |
| US20110189231A1 (en) * | 2008-06-17 | 2011-08-04 | Denis Leclerc | Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines |
| WO2010012069A1 (en) * | 2008-07-30 | 2010-02-04 | Folio Biotech Inc. | Multivalent vaccines based on papaya mosaic virus and uses thereof |
| WO2012078069A1 (en) | 2010-12-09 | 2012-06-14 | Iosif Grigorievich Atabekov | Spherical nano- and microparticles derived from plant viruses for the display of foreign proteins or epitopes |
| AU2012255595A1 (en) | 2011-05-13 | 2013-12-12 | Folia Biotech Inc. | Virus-like particles and process for preparing same |
| TR201905619T4 (tr) | 2011-06-09 | 2019-05-21 | Biomay Ag | Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri. |
| HK1203983A1 (en) * | 2012-04-02 | 2015-11-06 | Folia Biotech Inc. | Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines |
| JP2016531927A (ja) * | 2013-09-19 | 2016-10-13 | フォリア バイオテック インコーポレイテッド | 癌治療でのパパイヤモザイクウイルス及びウイルス様粒子 |
| WO2016176558A1 (en) * | 2015-04-30 | 2016-11-03 | The Regents Of The University Of California | Adjuvant particles comprising adenosine receptor antagonists |
| CN115956125A (zh) * | 2020-03-31 | 2023-04-11 | 医学噬菌体生物制药公司 | 用于产生病毒样颗粒的载体及其用途 |
| EP4277654A1 (en) | 2021-01-18 | 2023-11-22 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
| CN118684781A (zh) * | 2023-03-21 | 2024-09-24 | 深圳赫兹生命科学技术有限公司 | GnRH-VLP重组去势疫苗及其制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL79880A0 (en) | 1985-08-29 | 1986-11-30 | Inst Medical W & E Hall | Recombinant virus |
| US5977438A (en) | 1988-02-26 | 1999-11-02 | Biosource Technologies, Inc. | Production of peptides in plants as viral coat protein fusions |
| DE4006630A1 (de) | 1990-03-03 | 1991-09-12 | Behringwerke Ag | Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung |
| CA2089497A1 (en) | 1990-08-15 | 1992-02-16 | Lendon Payne | Self-assembling replication defective hybrid virus particles |
| US5443969A (en) * | 1992-10-29 | 1995-08-22 | Rutgers University | RNA packaging system |
| GB9414118D0 (en) | 1994-07-13 | 1994-08-31 | Axis Genetics Ltd | Modified plant viruses as vectors of heterologous peptides |
| CA2202761A1 (en) | 1994-10-18 | 1996-04-25 | Sean Nicholas Chapman | Method of producing a chimeric protein |
| GB9607899D0 (en) | 1996-04-17 | 1996-06-19 | Scottish Crop Research Inst | Virus-like particle |
| US6042832A (en) | 1996-08-28 | 2000-03-28 | Thomas Jefferson University | Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins |
| EP0980257A1 (en) * | 1997-05-01 | 2000-02-23 | Chiron Corporation | Use of virus-like particles as adjuvants |
| US6228368B1 (en) | 1997-10-06 | 2001-05-08 | Loyola University Of Chicago | Papilloma virus capsomere formulations and method of use |
| DE19752855C2 (de) | 1997-11-28 | 2003-04-03 | Bundesrepublik Deutschland Let | Retrovirale Pseudotyp-Vektoren mit modifizierten Oberflächen-Hüllproteinen und Verpackungszelle zu ihrer Herstellung für den selektiven Gentransfer |
| GB9806666D0 (en) | 1998-03-27 | 1998-05-27 | Stanley Margaret | Antigen preparation and use |
| JP2002522029A (ja) | 1998-07-27 | 2002-07-23 | ジェネンテック・インコーポレーテッド | コートタンパク質の改変によるファージ提示における改良した形質転換効率 |
| FR2786773B1 (fr) | 1998-12-03 | 2002-03-08 | Univ Paris Curie | Proteines d'enveloppe, methodes et utilisations |
| EP2351768B1 (en) | 1998-12-04 | 2014-06-18 | Biogen Idec MA Inc. | HBV core antigen particles with multiple immunogenic components attached via peptide ligands |
| DE19904800C1 (de) | 1999-02-05 | 2001-02-08 | Eberhard Hildt | Partikel zur Gentherapie |
| GB9921337D0 (en) * | 1999-09-09 | 1999-11-10 | Axis Genetics Plc | Modified plant viruses |
| GB9924352D0 (en) | 1999-10-14 | 1999-12-15 | Hellendoorn Koen | Methods,compositions and applications relating to the generation of novel plant viral particles |
| GB9924351D0 (en) * | 1999-10-14 | 1999-12-15 | Brennan Frank | Immunomodulation methods and compositions |
| US6730306B1 (en) | 2000-03-08 | 2004-05-04 | Large Scale Biology Corporation | Parvovirus vaccine as viral coat protein fusions |
| AUPQ661600A0 (en) | 2000-03-31 | 2000-05-04 | Macfarlane Burnet Centre For Medical Research Limited, The | A nucleic acid construct and methods related thereto |
| IT1317046B1 (it) * | 2000-06-16 | 2003-05-26 | Ist Superiore Sanita | Proteina di fusione, particelle virali chimeriche che la espongono sulcapside, piante infettate con tali particelle, loro usi e composizioni |
| CA2414396A1 (en) | 2000-06-26 | 2002-01-03 | The United States Of America, As Represented By The Secretary Of Agricul Ture | Production of vaccines using transgenic plants |
| WO2002004007A2 (en) | 2000-07-06 | 2002-01-17 | Georgetown University | Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof |
| GB0028319D0 (en) * | 2000-11-20 | 2001-01-03 | Univ Southampton | Materials and methods relating to fusion proteins for inducing an immune response |
| ITRM20010332A1 (it) * | 2001-06-11 | 2002-12-11 | Ist Superiore Sanita | Vaccini a subunita' e procedimenti per la loro produzione. |
| US8101189B2 (en) | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
| CA2434000C (en) * | 2002-07-05 | 2012-07-17 | Denis Leclerc | Adjuvant viral particle |
-
2003
- 2003-06-30 CA CA2434000A patent/CA2434000C/en not_active Expired - Fee Related
- 2003-06-30 DK DK03739913.6T patent/DK1523329T3/da active
- 2003-06-30 KR KR1020057000114A patent/KR20050044886A/ko not_active Withdrawn
- 2003-06-30 EP EP10179379A patent/EP2272525A3/en not_active Withdrawn
- 2003-06-30 MX MXPA05000287A patent/MXPA05000287A/es active IP Right Grant
- 2003-06-30 AU AU2003281246A patent/AU2003281246A1/en not_active Abandoned
- 2003-06-30 JP JP2004518318A patent/JP4953570B2/ja not_active Expired - Fee Related
- 2003-06-30 PT PT37399136T patent/PT1523329E/pt unknown
- 2003-06-30 ES ES03739913T patent/ES2431963T3/es not_active Expired - Lifetime
- 2003-06-30 BR BR0312474-6A patent/BR0312474A/pt not_active Application Discontinuation
- 2003-06-30 CN CN03815935XA patent/CN1665528B/zh not_active Expired - Fee Related
- 2003-06-30 WO PCT/CA2003/000985 patent/WO2004004761A2/en not_active Ceased
- 2003-06-30 EP EP03739913.6A patent/EP1523329B1/en not_active Expired - Lifetime
- 2003-07-01 US US10/609,417 patent/US7641896B2/en not_active Expired - Fee Related
-
2005
- 2005-01-25 NO NO20050396A patent/NO20050396L/no not_active Application Discontinuation
-
2009
- 2009-04-03 US US12/384,476 patent/US8282940B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20090280145A1 (en) | 2009-11-12 |
| US8282940B2 (en) | 2012-10-09 |
| BR0312474A (pt) | 2005-04-26 |
| HK1075214A1 (en) | 2005-12-09 |
| NO20050396L (no) | 2005-01-25 |
| WO2004004761A3 (en) | 2004-05-06 |
| EP2272525A3 (en) | 2011-11-16 |
| CN1665528B (zh) | 2013-05-15 |
| DK1523329T3 (da) | 2013-10-14 |
| KR20050044886A (ko) | 2005-05-13 |
| CA2434000C (en) | 2012-07-17 |
| AU2003281246A1 (en) | 2004-01-23 |
| EP2272525A2 (en) | 2011-01-12 |
| WO2004004761A2 (en) | 2004-01-15 |
| EP1523329B1 (en) | 2013-07-24 |
| US20050048082A1 (en) | 2005-03-03 |
| JP2006504644A (ja) | 2006-02-09 |
| CA2434000A1 (en) | 2004-01-05 |
| MXPA05000287A (es) | 2005-09-08 |
| CN1665528A (zh) | 2005-09-07 |
| US7641896B2 (en) | 2010-01-05 |
| JP4953570B2 (ja) | 2012-06-13 |
| PT1523329E (pt) | 2013-10-08 |
| EP1523329A2 (en) | 2005-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2431963T3 (es) | Partícula viral adyuvante | |
| ES2139879T5 (es) | Adyuvante de la mucosa no toxico. | |
| Cui et al. | Flagellin as a vaccine adjuvant | |
| Cui | DNA vaccine | |
| Brennan et al. | Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus | |
| US9339535B2 (en) | Vaccines and immunopotentiating compositions and methods for making and using them | |
| CN104395336A (zh) | 以计算方式优化的h5n1和h1n1流感病毒的广泛反应性抗原 | |
| ES2533345T3 (es) | Diferentes serotipos del virus de la estomatitis vesicular como vectores de expresión para regímenes de inmunización | |
| Narayanan et al. | Recombinant helical plant virus-based nanoparticles for vaccination and immunotherapy | |
| ES2924914T3 (es) | Vacuna contra rinovirus humano | |
| US20140161836A1 (en) | Carious tooth vaccine and preparation method | |
| ES2648337T3 (es) | Uso del PACAP como adyuvante molecular para vacunas | |
| Kammer et al. | Rabies vaccines: from the past to the 21st century | |
| Arnon et al. | Peptide-based synthetic recombinant vaccines with anti-viral efficacy | |
| HK1151730A (en) | Adjuvant viral particle | |
| HK1075214B (en) | Adjuvant viral particle | |
| JP5960064B2 (ja) | ヒトプロガストリンペプチドに対する免疫原性組成物 | |
| US20230100362A1 (en) | Conjugate Vaccines Containing Hydrazine-PEG-Hydrazine Linkers | |
| WO2008015309A1 (es) | Construcción peptídica dendrimérica para la prevención de la fiebre aftosa en animales. | |
| ES2358733T3 (es) | Vacuna derivada de levadura contra ipnv. | |
| Zaher et al. | The role of DNA vaccine as a control measure for viral disease | |
| Ben-Yedidia | A peptide-based vaccine against influenza | |
| Ramesh | Introduction to Recombinant Vaccines | |
| Falzarano | Edible vaccines: immunological response to hepatitis B virus nucleocapsid derived from transgenic plants | |
| Puig | Lipopeptide vaccines against foot and mouth disease |